Clinical Trials at Kootenai Clinic Cancer Services - Post Falls

As of June 2026, 83 paid clinical trials are recruiting at Kootenai Clinic Cancer Services - Post Falls in Post Falls, Idaho. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 15, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

83 clinical trials at Kootenai Clinic Cancer Services - Post Falls

·Clear filters·↓ Download CSV

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

for Malignant Solid Neoplasm

384 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06295367·Recruiting

Apply to this trial

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

for Metastatic Nasopharyngeal Carcinoma

Drug: Cabozantinib

92 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05904080·Phase 2·Recruiting

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

490 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

Mobile Health for Adherence in Breast Cancer Patients

for Anatomic Stage IV Breast Cancer AJCC v8

499 locations incl. Fairbanks

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06112613·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

537 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

237 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for Anatomic Stage I Breast Cancer AJCC v8

955 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05929768·Phase 3·Recruiting

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

820 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

454 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting

Apply to this trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

for Recurrent Endometrial Carcinoma

Drug: Selumetinib

293 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05554328·Phase 2·Recruiting

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

475 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

785 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting

Apply to this trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

for Clinical Stage III Cutaneous Melanoma AJCC v8

Drug: Cabozantinib

222 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05136196·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for Endometrial Carcinoma

403 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05256225·Phase 3·Recruiting

Apply to this trial

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

for Acute Lymphoblastic Leukemia

746 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 40 - 75·Accepts healthy volunteers

Code: NCT05334069·Recruiting

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

1021 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for Endometrial Adenocarcinoma

Drug: Ipilimumab

137 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05112601·Phase 2·Recruiting

Apply to this trial

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

for Metastatic Malignant Neoplasm in the Liver

446 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05040360·Phase 2·Recruiting

Apply to this trial

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

for Cigarette Smoking-Related Carcinoma

222 locations incl. Kingman

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05008848·Phase 3·Recruiting

Apply to this trial

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

for Adenocarcinoma of the Colon

472 locations incl. Fairbanks

Sponsor: NRG Oncology

Sex: All·Age: 45 - 70

Code: NCT05080673·Recruiting

Apply to this trial

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for Malignant Solid Neoplasm

843 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04871542·Recruiting

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

452 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Carthage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

for Plasma Cell Myeloma

642 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT04566328·Phase 3·Recruiting

Apply to this trial

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for Acral Lentiginous Melanoma

Drug: Ipilimumab

331 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04511013·Phase 2·Recruiting

Apply to this trial

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

for Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Drug: Bevacizumab

604 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04181060·Phase 3·Recruiting

Apply to this trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for Biochemically Recurrent Prostate Carcinoma

Drug: Apalutamide

342 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male·Age: 18+

Code: NCT04423211·Phase 3·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

for Metastatic Small Intestinal Adenocarcinoma

536 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04205968·Phase 2·Recruiting

Apply to this trial

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

for Malignancy

626 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: All ages

Code: NCT04242095·Recruiting

Apply to this trial

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

for Smoldering Plasma Cell Myeloma

Drug: Daratumumab

741 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03937635·Phase 3·Recruiting

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

Drug: Cabozantinib

578 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting

Apply to this trial

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

for Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

140 locations incl. Tucson

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03493425·Phase 2·Recruiting

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

1229 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting

Apply to this trial

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

for Breast Cancer

451 locations incl. Fairbanks

Sponsor: Canadian Cancer Trials Group

Sex: Female·Age: 35+

Code: NCT03488693·Phase 3·Recruiting

Apply to this trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for Castration Levels of Testosterone

334 locations incl. Gilbert

Sponsor: SWOG Cancer Research Network

Sex: Male·Age: 18+

Code: NCT03678025·Phase 3·Recruiting

Apply to this trial

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

for Anatomic Stage IV Breast Cancer AJCC v8

709 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03723928·Recruiting

Apply to this trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for Advanced Lung Non-Small Cell Carcinoma

Drug: Osimertinib

345 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03191149·Phase 2·Recruiting

Apply to this trial

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for Cardiotoxicity

577 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03418961·Phase 3·Recruiting

Apply to this trial